Simple Summary Triple-negative breast cancer (TNBC) is currently in the clinical research
spotlight because of the tumor's aggressive and invasive nature and the scarcity of …

Purpose There is a need to refine the prognosis of triple-negative breast cancer (TNBC)
patients after neoadjuvant chemotherapy (NAC) and to study the influence of the tumor …

Purpose Pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) is
associated with favourable outcomes of patients with triple-negative breast cancer (TNBC) …

Objective This study aimed to examine the prevalence and prognostic role of tumor
microenvironment (TME) in triple-negative breast cancer (TNBC) after neoadjuvant …

Simple Summary Neoadjuvant chemotherapy is now a standard of care not only to decrease
tumor size for breast conserving operation but also to assess drug response of an in situ …

Triple-negative breast cancer (TNBC) is particularly challenging due to the weak or absent
response to therapeutics and its poor prognosis. The effectiveness of neoadjuvant …

Background Although neoadjuvant chemotherapy (NAC) is currently the best therapy for
triple‐negative breast cancer (TNBC), resistance still occurs in a considerable proportion …

We developed a test to predict which patients will achieve pathological complete response
(pCR) to neoadjuvant chemotherapy (NAC) and which will have residual disease (RD) …

Simple Summary Pathological complete response (pCR) after neoadjuvant chemotherapy
can predict survival outcomes in patients with early triple negative breast cancer (TNBC) …

Background When triple-negative breast cancer (TNBC) patients have residual disease after
neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With …